Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings

Introduction: ALK inhibitors are one of the success stories in precision medicine for treating patients with advanced ALK-positive NSCLC. Nevertheless, developing countries have substantial constraints in using ALK inhibitors, with limited data from India. Methods: An audit of a prospectively collec...

Full description

Bibliographic Details
Main Authors: Akhil Kapoor, MD, DM, Vanita Noronha, MD, DM, Vijay Patil, MD, DM, Nandini Menon, MD, DNB, Amit Joshi, MD, DM, Amit Kumar, MD, DM, Ajay Kumar Singh, MD, DM, Abhishek Mahajan, MD, Amit Janu, MD, Rajiv Kumar, MD, Trupti Pai, MD, Anuradha Chougule, MD, Omshree Shetty, MD, Kumar Prabhash, MD, DM, ECMO
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:JTO Clinical and Research Reports
Subjects:
ALK-positive lung cancer
ALK inhibitors
Real-world data
Low-middle income countries
Crizotinib
Ceritinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001679

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001679

Similar Items